Last reviewed · How we verify
Rocuronium Bromide, Cisatracurium Besylate
Rocuronium Bromide, Cisatracurium Besylate is a Small molecule drug developed by NYU Langone Health. It is currently in Phase 2 development. Also known as: Zemurone, Nimbex.
At a glance
| Generic name | Rocuronium Bromide, Cisatracurium Besylate |
|---|---|
| Also known as | Zemurone, Nimbex |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease (PHASE4)
- Continuous Versus 1-min Oscillometric Arterial BP Monitoring (NA)
- Two Video Laryngoscopes (Laringocel® and C-MAC®) for First-Attempt Intubation in Adults Undergoing Elective Surgery (NA)
- Standardised Drug Provocation Testing in Perioperative Hypersensitivity (NA)
- Impact of Remimazolam on Prognosis After Bladder Cancer Surgery (PHASE4)
- Minimum Effective Dose of Incisional Local Infiltration Betamethasone for the Prevention of Pain After Spinal Surgery (NA)
- Effect of Magnesium Sulphate Pretreatment in Pediatric Abdominal Surgery (PHASE2, PHASE3)
- Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rocuronium Bromide, Cisatracurium Besylate CI brief — competitive landscape report
- Rocuronium Bromide, Cisatracurium Besylate updates RSS · CI watch RSS
- NYU Langone Health portfolio CI
Frequently asked questions about Rocuronium Bromide, Cisatracurium Besylate
What is Rocuronium Bromide, Cisatracurium Besylate?
Rocuronium Bromide, Cisatracurium Besylate is a Small molecule drug developed by NYU Langone Health.
Who makes Rocuronium Bromide, Cisatracurium Besylate?
Rocuronium Bromide, Cisatracurium Besylate is developed by NYU Langone Health (see full NYU Langone Health pipeline at /company/nyu-langone-health).
Is Rocuronium Bromide, Cisatracurium Besylate also known as anything else?
Rocuronium Bromide, Cisatracurium Besylate is also known as Zemurone, Nimbex.
What development phase is Rocuronium Bromide, Cisatracurium Besylate in?
Rocuronium Bromide, Cisatracurium Besylate is in Phase 2.
Related
- Manufacturer: NYU Langone Health — full pipeline
- Also known as: Zemurone, Nimbex
- Compare: Rocuronium Bromide, Cisatracurium Besylate vs similar drugs
- Pricing: Rocuronium Bromide, Cisatracurium Besylate cost, discount & access